Rapamycin and longevity: what the human evidence shows

My articles

Rapamycin and longevity: big promise in animals, limited evidence in humans

By Dr. Asnat Raziel, bariatric surgeon specializing in obesity treatment, metabolic health and healthy longevity; Director of the Multidisciplinary Center for Obesity Treatment, Assia Medical, Assuta Ramat HaChayal, Tel Aviv

Rapamycin and longevity: what we really know

Rapamycin and longevity are two words that intrigue many people in the longevity world. This drug is one of the most interesting candidate drugs in aging research. It extended lifespan in mice and influenced key mechanisms of cell growth. Today, some longevity clinics around the world already prescribe it to healthy people.

However, a scientific review in the journal Aging cools the excitement. As of October 2026, there is no clinical proof that rapamycin extends the lives of healthy people. Nor is there proof that it slows their aging.

What is rapamycin and how does it work?

Rapamycin is also known as sirolimus. It suppresses and regulates the immune system, and transplant doctors have used it for many years. Researchers isolated it in 1975 from a soil bacterium found on Easter Island. Later, scientists discovered that it inhibits the mTOR pathway (mechanistic target of rapamycin).

The mTOR pathway acts as a kind of control system for the cell. It responds to amino acids, energy, insulin and growth factors. When nutrients are plentiful, it promotes growth and protein production. By contrast, when its activity drops, the cell shifts resources toward maintenance and repair. As a result, autophagy increases. Autophagy is the process in which the cell breaks down and recycles damaged components (I discuss it further in my article on zombie cells and autophagy). That is why mTOR inhibition has become a central strategy in aging research.

Why does rapamycin generate so much excitement?

The excitement comes mainly from animal studies. In the US Interventions Testing Program, genetically diverse mice received rapamycin. In a landmark 2009 study in Nature, the drug extended the lives of both males and females, even when treatment started late in life. Other studies also showed a delay in age-related diseases. I have written before about other drugs that target aging, such as GLP-1 drugs against aging.

Still, success in mice does not guarantee success in humans. Doses, metabolism, causes of death and lifespan differ greatly between species.

What did the review examine?

Jacob Hands, Michael Lustgarten, Lee Frame and Bradley Rosen wrote the review, which appeared in August 2025. They examined the use of low-dose rapamycin and similar drugs in healthy adults. These similar drugs are called rapalogs, meaning rapamycin analogs.

This is a critical review, not a new trial. The authors found fewer than a dozen relevant studies, and many of them were small and short. In addition, the studies varied widely in dose, frequency and outcome measures. Their conclusion was cautious: animal research looks promising, but human data are still insufficient.

Rapamycin and longevity: signals in immune function

One of the interesting findings concerns the immune system in older age. A study of 218 older adults tested low doses of everolimus, a drug similar to rapamycin. Treatment improved the response to the flu vaccine by about 20%. In addition, the researchers saw changes in T cells that matched a younger immune profile. On the downside, mouth ulcers were frequent in the treatment group.

Other studies tested whether mTOR inhibitors reduce respiratory infections in older adults. In phase 2b and phase 3 trials, the phase 2b trial showed a benefit, but the phase 3 trial did not replicate it. So this is a signal for future research, not proof for routine treatment.

What about lifespan itself?

Here lies the main limitation. No clinical study has shown that rapamycin extends human life. Such a trial would require thousands of participants and many years of follow-up. Therefore, researchers look at indirect markers, such as immune function, walking speed, grip strength and epigenetic clocks. These markers matter, but they are no substitute for proof of fewer diseases and longer lives.

The review also reanalyzed data from a small trial using the PhenoAge model, which estimates biological age from blood tests. The rapamycin group showed an estimated 3.96-year drop in biological age, compared with a 0.15-year rise on placebo. However, the authors themselves called this finding “suggestive at best.” They relied on group averages and could not test for statistical significance.

The PEARL trial: what did the new data add?

In April 2025, researchers published the results of the PEARL trial. This was a 48-week randomized, double-blind trial that included 114 adults aged 50 to 85. Participants took 5 mg or 10 mg of rapamycin once a week, or a placebo. Treatment did not reduce abdominal fat, which was the primary outcome.

Even so, women who took 10 mg gained lean body mass and reported less pain. In addition, participants who took 5 mg reported better emotional well-being. Overall, treatment was generally safe. But the group was small, and the compounded formulation absorbed less well than a commercial one. In other words, PEARL does not prove that rapamycin extends life either.

A possible effect on muscle

The mTOR pathway plays a central role in building muscle protein. This raises a fundamental question: could slowing aging harm muscle? The findings are mixed. In one study, a 16 mg dose of rapamycin blocked the rise in muscle protein synthesis after exercise. By contrast, another study found no change in protein synthesis at rest.

This point matters. Muscle mass and strength keep us independent in older age, as I explain in my guide to preserving muscle mass during weight loss. The review does not prove that rapamycin causes muscle loss. Yet it also does not rule out a blunted response to training. For a broader view of how exercise supports a long, healthy life, see my article on fitness for longevity.

Side effects and warning signs

At low doses and for short periods, most participants tolerated treatment well. However, the studies documented several changes that call for attention:

Mouth ulcers, mainly in the everolimus trial.
Higher triglycerides and a trend toward higher VLDL, a type of blood fat.
A rise in HbA1c, the average blood sugar over the past three months.
Lower albumin and changes in blood counts.
More anxiety at certain doses, in a small study of young men.

The changes in blood fats, blood sugar and albumin appeared in a trial in people aged 70 to 95. In addition, rapamycin can interact with other medications. At transplant doses, it causes infections, impaired wound healing and metabolic harm. Admittedly, we cannot directly apply findings from transplant patients to healthy people. On the other hand, there is no basis for assuming that long-term low-dose use is risk-free.

Rapamycin and longevity: no proven dose yet

Clinics offer weekly or every-other-week regimens. Yet the review stresses that there is no established dose-response curve for extending healthspan. Nobody knows the right dose, the right age to start or how long to treat. Moreover, rapamycin is a generic drug, so there is little incentive to fund a large, multi-year trial.

The bottom line on rapamycin and longevity

Rapamycin is a fascinating research candidate. It acts on a central pathway in the biology of aging and extends lifespan in animals. However, no one has shown that it extends life or slows aging in healthy humans. There is also no agreed dose, and its long-term safety remains unknown.

For now, then, the link between rapamycin and longevity belongs mainly to the world of research. Off-label use is appropriate, if at all, only within a careful medical setting, with clinical and laboratory monitoring. Ultimately, the goal of healthy longevity is years of health and independence, an approach I follow at my geroscience longevity clinic. It pays to stay curious, while also demanding proof before an experimental treatment becomes routine.

The information in this article is general and does not replace personal medical advice.